Department of Preventive Medicine, Armed Forces Medical Command, Seongnam.
Department of Medicine, Third Republic of Korea Army Command, Yongin.
J Infect Dis. 2018 Apr 11;217(9):1417-1420. doi: 10.1093/infdis/jiy037.
As there is no effective treatment against hemorrhagic fever with renal syndrome (HFRS), the development of effective vaccine is important. An inactivated hantavirus vaccine (IHV) has been used in Korea, but there has been controversy regarding its effectiveness. We conducted a case-control study to evaluate the vaccine effectiveness (VE) of IHV against HFRS in the Korean military. Unadjusted and adjusted VEs of IHV were 59.1% and 58.9%, respectively. VE was higher in divisions with high incidence of HFRS (unadjusted VE, 71.4%; adjusted VE, 78.7%). Our study demonstrated the moderate effectiveness of IHV in high-risk populations residing in endemic area.
由于目前尚无针对肾综合征出血热（HFRS）的有效治疗方法，因此开发有效的疫苗非常重要。一种灭活汉坦病毒疫苗（IHV）已在韩国使用，但关于其有效性存在争议。我们进行了一项病例对照研究，以评估 IHV 对韩国军队中 HFRS 的疫苗效力（VE）。IHV 的未调整和调整 VE 分别为 59.1%和 58.9%。在 HFRS 发病率较高的师级单位，VE 更高（未调整 VE，71.4%；调整 VE，78.7%）。我们的研究表明，在流行地区居住的高危人群中，IHV 的有效性为中等。
